A Phase 2 interventional study of Triamcinolone Acetonide and Semi-automated Suprachoroidal Microcatheter in Diabetic Macular Edema, sponsored by Oxular Limited. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.
Sponsored by Oxular Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing Triamcinolone Acetonide in Macular Edema — 1 open to participants now, 1 under way, none of them phase 3. Triamcinolone Acetonide · Macular Edema.
Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, this one is the 18th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 25th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 26 studies testing Triamcinolone Acetonide in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Healthy volunteers
By country, each count listing its studies:
Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 10 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 75 across the 25 interventional studies. Of the 22 that completed or were terminated, 5 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 26 have an industry lead sponsor. The 10 most frequent:
Oxular Limited is the lead sponsor of 3 studies on the registry; none are open to participants now.
Oxular Limited has 2 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to evaluate the safety and tolerability of suprachoroidal microcatheterization with the Oxulumis® device for a randomized treatment with two dose levels of Triesence® in subjects with Diabetic Macular Edema.
Twenty-four (24) week, randomized, two-arm, single-masked, clinical trial to evaluate safety, tolerability, and to explore the efficacy of two dose levels of suprachoroidal triamcinolone acetonide suspension (Triesence®, 2.4 mg, and 4.0mg) administered using the Oxulumis® microcatheterization device in subjects with previously treated Diabetic Macular Edema.
After a screening period, approximately 20 eligible Diabetic Macular Edema subjects will be treated using a 1:1 ratio to receive a single administration of one of two dose levels of triamcinolone acetonide (low dose, 2.4mg. or mid-dose, 4.0mg, respectively). If for any reasons treatment in randomized subjects cannot be completed, additional consecutive subjects will be randomized until the target number of approximately 20 treated subjects is reached.
From Week 4, subjects will be assessed for the need for follow-on treatment. The follow-up period after treatment administration will be up to twenty-four (24) weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization. A single treatment with 2.4mg/60µl Triesence® will be applied.
Drug: Triamcinolone Acetonide · Device: Semi-automated Suprachoroidal Microcatheter
The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization. A single treatment with 4.0mg/100µl Triesence® will be applied.
Drug: Triamcinolone Acetonide · Device: Semi-automated Suprachoroidal Microcatheter
Single suprachoroidal Administration of Triamcinolone acetonide
Also known as: Triesence®
Ophthalmic Adminstration Device
Also known as: Oxulumis®
Frequency of Ocular Adverse Events, Systemic Adverse Events, Serious, and Treatment-emergent Non-serious Adverse Events
Treatment-emergent ocular adverse events are defined as an ocular event that emerges following the start of administration of Triesence® with the Oxulumis® microcatheter at Visit 2 (Baseline, Day 0)
Time frame: Day 0 up to Week 24 (per protocol individual trial duration per participant)
Frequency of Adverse Device Effects and Frequency of Serious Adverse Device Effects
Adverse device effects a are defined as effects that emerge following the start of administration of the Oxulumis® microcatheter at Visit 2 (Baseline, Day 0)
Time frame: Day 0 up to Week 24 (per protocol individual trial duration per participant)
Mean Change in IOP Through Week 24 Compared to Baseline
Change from baseline in intraocular pressure as measured by applanation tonometry or standard IOP measuring devices
Time frame: Baseline, Week 4, Week 12, and Week 24
Mean Change in Central Subfield Thickness (CST) at Study Visits Through Week 24 Compared to Baseline
Change from Baseline in central subfield thickness (CST), to image the macular edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT) and was read at the site. A negative change from baseline value represents a reduction in macular edema.
Time frame: Baseline, Week 4, Week 12, and Week 24
Mean Change in Best-Corrected Visual Acuity at Study Visits Through Week 24 Compared to Baseline
Best corrected visual acuity (BCVA) using the ETDDRS methodology) with assessment starting at a distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), with a higher score indicating better visual acuity.
Time frame: Baseline, Week 4, Week 12, and Week 24
Number of Participants With Change in Best Corrected Visual Acuity (BCVA) Categorized as at Least 5, 10, and 15 Letter Gain Compared to Baseline at Study Visits Through Week 24
Measure Description: Best corrected visual acuity (BCVA) at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), with a higher score indicating better visual acuity. The Outcome Measure provides the number of participants, who have at least a 5, 10, or 15 letter BCVA gain at the respective study visit compared to their baseline BCVA assessment
Time frame: Baseline, Week 4, Week12, and Week 24
Consecutive recruitment at participating sites in the US. Enrolment will be continued, until at least 20 randomized subjects could also be treated, i.e. total enrolment could be higher than 20.
| Milestone | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg |
|---|---|---|
| Started | 13 | 12 |
| Efficacy evaluable population | 10 | 10 |
| Per protocol population | 5 | 9 |
| Completed | 12 | 12 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Treatment-emergent ocular adverse events are defined as an ocular event that emerges following the start of administration of Triesence® with the Oxulumis® microcatheter at Visit 2 (Baseline, Day 0)
| Participants | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg |
|---|---|---|
| Number of Participants with Ocular Treatment-Emergent Adverse Events | 10 | 8 |
| Number of Participants with Systemic (Non-Ocular) Treatment-Emergent Adverse Events | 3 | 5 |
| Number of Participants with Ocular Treatment-Emergent Serious Adverse Events | 0 | 0 |
| Number of Participants with Systemic (Non-Ocular) Treatment-Emergent Serious Adverse Events | 0 | 0 |
Adverse device effects a are defined as effects that emerge following the start of administration of the Oxulumis® microcatheter at Visit 2 (Baseline, Day 0)
| Participants | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg |
|---|---|---|
| Number of Participants with Adverse Device Effects | 0 | 0 |
| Number of Participants with Serious Adverse Device Effects | 0 | 0 |
Change from baseline in intraocular pressure as measured by applanation tonometry or standard IOP measuring devices
| mmHg | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg |
|---|---|---|
| Mean Change in IOP from Baseline at Week 4 | 1.6 ± 5.0 | 1.0 ± 2.5 |
| Mean Change in IOP from Baseline at Week 12 | 1.6 ± 2.9 | -0.2 ± 4.4 |
| Mean Change in IOP from Baseline at Week 24 | 1.3 ± 2.1 | 2.0 ± 3.6 |
Change from Baseline in central subfield thickness (CST), to image the macular edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT) and was read at the site. A negative change from baseline value represents a reduction in macular edema.
| µm | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg |
|---|---|---|
| Mean Change in Central subfield thickness (CST) at Week 4 compared to baseline | -112.3 ± 136.2 | -172.0 ± 234.1 |
| Mean Change in Central subfield thickness (CST) at Week 12 compared to baseline | -63.3 ± 71.4 | -132.8 ± 133.6 |
| Mean Change in Central subfield thickness (CST) at Week 24 compared to baseline | -62.5 ± 45.0 | -127.7 ± 198.2 |
Best corrected visual acuity (BCVA) using the ETDDRS methodology) with assessment starting at a distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), with a higher score indicating better visual acuity.
| ETDRS letters | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg |
|---|---|---|
| Mean Change in Best-Corrected Visual Acuity (ETDRS) at Week 4 Compared to Baseline | 4.5 ± 4.7 | 10.6 ± 10.0 |
| Mean Change in Best-Corrected Visual Acuity (ETDRS) at Week 12 Compared to Baseline | 0.9 ± 6.0 | 9.0 ± 9.6 |
| Mean Change in Best-Corrected Visual Acuity (ETDRS) at a Week 24 Compared to Baseline | 4.8 ± 11.8 | 11.0 ± 11.5 |
Measure Description: Best corrected visual acuity (BCVA) at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), with a higher score indicating better visual acuity. The Outcome Measure provides the number of participants, who have at least a 5, 10, or 15 letter BCVA gain at the respective study visit compared to their baseline BCVA assessment
| Participants | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg |
|---|---|---|
| Week 4 At Least 5 Letter Gain in BCVA (ETDRS) compared to baseline | 5 | 6 |
| Week 12 At Least 5 Letter Gain in BCVA (ETDRS) compared to baseline | 1 | 3 |
| Week 24 At Least 5 Letter Gain in BCVA (ETDRS) compared to baseline | 2 | 2 |
| Week 4 At Least 10 Letter Gain in BCVA (ETDRS) compared to baseline | 1 | 5 |
| Week 12 At Least 10 Letter Gain in BCVA (ETDRS) compared to baseline | 1 | 2 |
| Week 24 At Least 10 Letter Gain in BCVA (ETDRS) compared to baseline | 2 | 2 |
| Week 4 At Least 15 Letter Gain in BCVA (ETDRS) compared to baseline | 0 | 3 |
| Week 12 At Least 15 Letter Gain in BCVA (ETDRS) compared to baseline | 0 | 1 |
| Week 24 At Least 15 Letter Gain in BCVA (ETDRS) compared to baseline | 2 | 1 |
Collected over Day 0 up to Week 24. The maximum interval of trial participation was 24 weeks, but per protocol participants ended their trial participation starting at Week 4, if they met criteria for follow-on therapy to treat Diabetic Macular Edema (DME). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Suprachoroidal Triamcinolone Acetonide 2.4mg | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| Suprachoroidal Triamcinolone Acetonide 4.0mg | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| Event | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg |
|---|---|---|
| Conjunctival haemorrhage - Study EyeEye disorders | 8/13 | 7/12 |
| Eye Pain - Study EyeEye disorders | 2/13 | 4/12 |
| SinusitisInfections and infestations | 0/13 | 3/12 |
| Conjunctival hyperemia - Study EyeEye disorders | 3/13 | 1/12 |
| Treatment Failure (Trial procedure not completed in the study eye)General disorders | 3/13 | 2/12 |
| Underdose - Treatment Study EyeInjury, poisoning and procedural complications | 2/13 | 0/12 |
| Wrong route - Treatment Study EyeInjury, poisoning and procedural complications | 2/13 | 0/12 |
| AnemiaBlood and lymphatic system disorders | 0/13 | 1/12 |
| Blepharitis - Study EyeEye disorders | 0/13 | 1/12 |
| Cataract - Study EyeEye disorders | 1/13 | 1/12 |
Safety Population (all subjects eligible and randomized)
| Age, Continuous(years) | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg | Total |
|---|---|---|---|
| Mean | 62.8 ± 8.32 | 63.2 ± 6.78 | 63.0 ± 7.46 |
| Sex: Female, Male(Participants) | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg | Total |
|---|---|---|---|
| Female | 3 | 5 | 8 |
| Male | 10 | 7 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 9 |
| Not Hispanic or Latino | 9 | 7 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 12 | 11 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg | Total |
|---|---|---|---|
| United States | 13 | 12 | 25 |
| Diabetes Type(Participants) | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg | Total |
|---|---|---|---|
| Type 1 | 1 | 0 | 1 |
| Type 2 | 12 | 12 | 24 |
| Duration of Diabetes (years)(years) | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg | Total |
|---|---|---|---|
| Mean | 19.4 (1.3 to 45.1) | 20.3 (6.0 to 34.5) | 19.9 (1.3 to 45.1) |
| Duration of DME (years), mean (min-max)(years) | Suprachoroidal Triamcinolone Acetonide 2.4mg | Suprachoroidal Triamcinolone Acetonide 4.0mg | Total |
|---|---|---|---|
| Mean | 2.7 (0.2 to 7.2) | 4.2 (0.5 to 9.1) | 3.4 (0.2 to 9.1) |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Nov 2023, 14 months.
Results were first posted in Nov 2024, 11 months after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 14 months is below that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide
Oxular Limited